Next generation sequencing redefines a triple negative essential thrombocythaemia as double‐positive with rare mutations on JAK 2  V617 and MPL W515 hotspots

Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients

(2015) X. Cabagnols et al.   BLOOD

Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms

(2015) J-P Defour et al.   LEUKEMIA

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors

(2014) C. Marty et al.   BLOOD

Impact of isolated germline JAK2V617I mutation on human hematopoiesis

(2013) A. J. Mead et al.   BLOOD

GermlineJAK2Mutation in a Family with Hereditary Thrombocytosis

(2012) Adam J. Mead et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients

(2011) Carlos Besses et al.   BRITISH JOURNAL OF HAEMATOLOGY

MPL Mutation Profile in JAK2 Mutation-negative Patients With Myeloproliferative Disorders

(2011) Wanlong Ma et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia

(2010) E. Antonioli et al.   HAEMATOLOGICA

Substitution of Pseudokinase Domain Residue Val-617 by Large Non-polar Amino Acids Causes Activation of JAK2

(2008) Alexandra Dusa et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mutation Profile of JAK2 Transcripts in Patients with Chronic Myeloproliferative Neoplasias

(2008) Wanlong Ma et al.   JOURNAL OF MOLECULAR DIAGNOSTICS